Skip to main content
Cytogen, Inc. logo

Cytogen, Inc. — Investor Relations & Filings

Ticker · 217330 ISIN · KR7217330000 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2021-11-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 217330

About Cytogen, Inc.

https://www.cytogenlab.com/

Cytogen, Inc. is a biotechnology company specializing in liquid biopsy platforms for precision oncology. The company has developed proprietary technology for the rapid isolation and analysis of viable Circulating Tumor Cells (CTCs) from whole blood. Its core offering, the SmartBiopsy Platform, utilizes a high-density microporous chip with microfluidics and nanotechnology to capture CTCs efficiently. This non-invasive diagnostic approach is designed to support early cancer detection, treatment monitoring, and the advancement of personalized medicine for cancer patients.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Cytogen' covering the period from January 1, 2021, to September 30, 2021. It contains detailed corporate information, management changes, capital structure, and business descriptions, which are characteristic of a formal quarterly financial report filed with regulatory bodies (Financial Services Commission and Korea Exchange). It is not an announcement of a report, but the report itself. 9M 2021
2021-11-15 Korean
전환청구권행사(제3회차 CB)
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification regarding the exercise of conversion rights for convertible bonds (CB) by the company CytoGen. It details the number of shares issued, the conversion price, and the remaining balance of the convertible bonds. This type of filing, which relates to changes in capital structure through the conversion of debt into equity, falls under the 'Share Issue/Capital Change' category.
2021-10-27 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the acquisition and changes in shareholding by T&C Asset Management in the company Cytogen. Since this is a specific regulatory disclosure regarding significant share ownership thresholds, it falls under the 'Major Shareholding Notification' category.
2021-10-08 Korean
전환가액의조정(제4회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from the company 'CytoGen' regarding the adjustment of the conversion price for its 4th series convertible bonds. It details the specific price adjustment, the change in the number of convertible shares, the calculation methodology based on market price averages, and the effective date. This type of disclosure regarding capital structure changes and convertible debt instruments falls under the 'Capital/Financing Update' category.
2021-08-20 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Cytogen, Inc.' covering the period from January 1, 2021, to June 30, 2021. It contains detailed financial information, business descriptions, management changes, and capital structure updates. According to the provided definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) is classified as an Interim / Quarterly Report (IR). H1 2021
2021-08-17 Korean
기타경영사항(특허권취득)(자율공시)(전립선특이 막항원 기반 전립선암환자 스크리닝 방법 일본특허 취득)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from CytoGen regarding the acquisition of a patent in Japan for a prostate cancer screening method. It is filed as a 'voluntary disclosure' (자율공시) under the category of 'Other Management Matters' (기타 경영사항). Since it does not fit into specific categories like M&A, financial reports, or director dealings, it falls under the general regulatory filing category.
2021-07-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.